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The susceptibility to several oligopeptide and amino acid antifungals of a Saccharomyces cerevisiae strain
carrying multiple deletions in yeast multidrug resistance genes was compared to transformants containing the
CDR1, CDR2, or MDR1 genes that encode the major Candida albicans drug efflux pumps. Recombinant yeast
strains overexpressing Cdr1p and Cdr2p showed enhanced susceptibilities to all tested oligopeptide antifun-
gals. The enhanced susceptibilities of multidrug-resistant yeast strains to oligopeptide antifungals corre-
sponded to higher rates of oligopeptide uptake. Yeast cells overexpressing Cdr1p or Cdr2p effluxed protons at
higher rates than the reference cells lacking these ABC transporters. An increased plasma membrane elec-
trochemical gradient caused by the functional overexpression of Cdr1p or Cdr2p appeared to increase cellular
susceptibility to oligopeptide antifungals by stimulating their uptake via oligopeptide permeases.
The frequency of fungal infections in immunocompromised
patients and mortality due to invasive mycoses continue to be
important clinical problems, and opportunistically pathogenic
Candida species remain one of the leading causes of nosoco-
mial bloodstream infections worldwide (13, 31, 35). Candida
albicans comprises nearly half of the isolates of candidemia
(44). The repertoire of antifungal chemotherapeutic agents is
very limited, and although new antifungal drugs, such as vori-
conazole and caspofungin, have been introduced into clinical
practice in recent years, the development of resistance, often
multidrug resistance (MDR), has become increasingly signifi-
cant (23).
The molecular mechanism underlying MDR is overexpres-
sion of membrane proteins belonging to members of a family
of ATP-binding cassette (ABC) transporters or the major fa-
cilitator superfamily. In Candida albicans, Cdr1p and Cdr2p
were identified as the major ABC drug transporters, while
CaMdr1p and FLU1p are the main representatives of the
major facilitator superfamily (36). The substrate specificity
spectrum of fungal MDR transporters includes many thera-
peutically important antifungal drugs, including azole antifun-
gals (40). The development of the MDR phenotype in C.
albicans clinical strains isolated from patients subjected to an-
tifungal chemotherapy with fluconazole is a well-documented
phenomenon (1, 10, 11), and fluconazole is widely used for
antifungal prophylaxis in immunocompromised patients (31).
There is a need for new antifungals that circumvent MDR.
It was previously shown that recombinant yeast cells over-
expressing the C. albicans Cdr1p drug efflux pump were
paradoxically more susceptible to the action of oligopeptidic
antifungal agents containing N3-(4-methoxyfumaroyl)-L-2,3-
diaminopropanoic acid (FMDP). It was suggested that the
observed hypersusceptibility might be due to the increased
uptake of FMDP peptides mediated by oligopeptide per-
meases (27). In the present study, the effects of several
structurally unrelated antifungal oligopeptides and amino
acids were investigated in MDR clinical isolates of Candida
albicans and genetically modified strains of the model yeast
Saccharomyces cerevisiae that overexpress genes encoding C.
albicans Cdr1p, Cdr2p, or Mdr1p drug efflux pumps.
MATERIALS AND METHODS
Chemicals. Nva-FMDP and Lys-Nva-FMDP were synthesized by R. Andrusz-
kiewicz (3). Methods for the synthesis of oligopeptides containing oxalysine
(OLys), m-fluorophenylalanine (FPhe), or 5-fluoroorotic acid were described
previously (4, 21, 43). Nikkomycin X/Z was a gift from H. Za¨hner, University of
Tu¨bingen, Germany. Fluconazole was from Pliva Krakow (Cracow, Poland).
Histatin 5 (DSHAKRHHGYKRKFHEKHHSHRGY) and other chemicals were
from Sigma or Calbiochem.
Yeast strains and growth conditions. The yeast strains used in this investiga-
tion are presented in Table 1. S. cerevisiae AD12345678 (hereafter denoted strain
AD) was kindly provided by A. Goffeau, Universite´ Catholique de Louvain,
Belgium. The AD-derived MDR cells were obtained by previously described
methods (14, 37, 42). The AD cells were propagated in yeast-nitrogen base-
glucose (YNBG) medium containing 0.67% YNB without amino acids and
ammonium sulfate (Difco), 2% glucose, and 4 mg/ml of L-proline (or, if indi-
cated, 1 mg/ml of L-glutamate) supplemented with L-histidine at 40 g/ml and
uracil at 30 g/ml, while the AD-derived transformants were maintained in a
similar medium lacking uracil. C. albicans cells were propagated in 2% glucose,
1% yeast extract, 1% Bacto peptone medium. C. albicans B3, B4, Gu4, and Gu5
clinical isolates were kindly provided by Joachim Morschha¨user, Wu¨rzburg,
Germany. Gu4 and B3 are fluconazole-sensitive isolates obtained from early
infection episodes, while Gu5 and B4 are the corresponding fluconazole-resistant
isolates obtained from later episodes in the same patients treated with flucon-
azole (10). For each sensitive/resistant pair, comparison of CARE-2 fingerprint
hybridization patterns confirmed that a single strain was responsible for the
recurrent infection. Reverse transcription-PCR, Northern blotting, and sodium
dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the plasma mem-
* Corresponding author. Mailing address: Department of Pharmaceu-
tical Technology & Biochemistry, Gdan´sk University of Technology, 11/12
Narutowicza St., 80-952 Gdan´sk, Poland. Phone: 48 583472107. Fax: 48
583471144. E-mail: milewski@altis.chem.pg.gda.pl.
 Published ahead of print on 15 September 2008.
4057
brane preparations indicated the molecular basis of the phenotypes ascribed in
Table 1.
Susceptibility testing methods. MICs of antifungals were determined by the
microdilution methods using 96-well microtiter plates. MICs for C. albicans
clinical isolates were determined in RPMI-1640 medium using the CLSI M27-A2
document recommendations (30). For S. cerevisiae recombinants, most condi-
tions were the same, but an appropriately supplemented YNBG medium (see
above) was used, and incubation was for 24 h at 30°C. Turbidity in individual
wells was measured with a plate reader (Victor3; PerkinElmer). MIC was defined
as a drug concentration that gave at least an 80% decrease in turbidity relative
to that of the drug-free growth control.
Determination of peptide and amino acid uptake rates. Initial velocities of
oligopeptide or amino acid uptake were determined using a modification of the
method of Payne and Nisbet (32). Yeast cells grown in the YNBG-proline
medium were harvested, washed, and suspended in 50 mM phosphate-citrate
buffer, pH 6.0, containing 1% glucose, to a final optical density at 660 nm
(OD660) of 1.0. The cell suspension was preincubated for 10 min at 30°C, and a
peptide or amino acid solution was added to give the final concentration of 50
M. In some experiments, 100 M fluconazole was added at the beginning of the
preincubation. Suspensions supplemented with 10 mM NaN3 were used as neg-
ative controls to correct for the background passive binding of each oligopeptide/
amino acid to the cells. A suspension without an oligopeptide/amino acid was
used as a blank. Samples of 1 ml of cell suspension, withdrawn at zero time and
at 5-min intervals, were filtered through Whatman GF/C filters. Samples of 200
l from each filtrate were combined with 2-ml portions of 0.1 M tetraborate-HCl
buffer, pH 6.2 (oligopeptide uptake determination) or pH 8.4 (amino acid uptake
determination). Fluorescamine in acetone (0.15 mg/ml and 500 l) was added,
and the resulting fluorescence intensities were measured (excitation, 390 nm;
emission, 485 nm). Initial uptake rates were determined from the plots of the
oligopeptide/amino acid remaining versus time. Standard curves were generated
for each oligopeptide and amino acid after dissolution in the appropriate tet-
raborate-HCl buffer and treatment with fluorescamine.
Efflux of oligopeptides and amino acids from yeast cells. AD, ADCDR1, or
ADCDR2 cells were grown in YNBG to the logarithmic phase of growth, har-
vested, washed three times in water, and resuspended to an OD660 of 1.0 in 50
mM phosphate buffer, pH 6.0, containing 5 mM 2-deoxy-D-glucose (2DG). Cell
suspensions were incubated for 2 h at 30°C with gentle shaking, and the cells
were harvested, washed three times in water, and resuspended in 50 mM phos-
phate-citrate buffer, pH 4.0. Amino acids or oligopeptides (200 M) were added,
and the cell suspensions were incubated for 60 min at 30°C with gentle shaking.
Samples of the cell suspensions were collected at 10-min time intervals to mon-
itor amino acid/oligopeptide uptake by the fluorescamine method (see above).
Amino acid/oligopeptide-loaded cells were harvested, washed two times in water,
and resuspended at an OD660 of 1.0 in prewarmed (30°C) 50 mM phosphate
buffer, pH 6.0. After a 5-min preincubation, glucose (10 mM) was added and cell
suspensions were incubated at 30°C with gentle shaking. Culture supernatants
were collected at 5-min time intervals to monitor the appearance of effluxed
amino acid/oligopeptide by the fluorescamine method. Yeast cell cultures treated
as above, except for loading with an amino acid/oligopeptide, were used as a
negative control to detect a background level of any fluorescamine-reactive
compounds extruded by the cells. In separate experiments, cells deenergized by
incubation with 2DG were loaded with rhodamine 6G (10 M) instead of an
amino acid/oligopeptide. An active glucose-dependent extrusion of the dye was
measured as described previously (45).
Other methods. Amino acids released from the oligopeptides by hydrolytic
enzymes present in cell extracts from the yeast cells were quantified using the
Cd-ninhydrin method (28). Intracellular pH was determined by the method of
Bracey et al. with 5(6)-carboxyfluorescein diacetate-succinimidyl ester (CFDA-
SE) as a fluorescent probe (7). The initial rates of proton efflux were determined
as described previously (18).
RESULTS
Microorganisms used in the study. This study used as a
model system the recombinant S. cerevisiae AD strain, deleted
of seven MDR transporters (9), and its transformants overex-
pressing either CDR1, CDR2, or MDR1 genes encoding the
major drug effluxing pumps of C. albicans. In all transformants,
each gene of interest was expressed from the centromeric
pYEUra3 plasmid under the control of its natural promoter
(14, 42). C. albicans clinical isolates that developed resistance
to fluconazole during antifungal chemotherapy with this drug
were also tested. The resistance of isolates Gu5 and B4 is due
to the documented overexpression of CDR1 and/or CDR2 in
the former and MDR1 in the latter (10, 11). Their matched
fluconazole-sensitive isolates Gu4 and B3, respectively, exhib-
ited basal expression of these resistance genes.
Growth inhibition of MDR yeast by oligopeptide and amino
acid antifungals. The in vitro susceptibilities of the strains de-
scribed above to several antifungal oligopeptides and amino acids
were determined. A set of the antifungal peptides included the
following: 5-FO-L-leucyl-L-leucine 1, three oligopeptides incorpo-
rating OLys 2 to 4, a dipeptide and a tripeptide incorporating
FPhe 5 and 6, two oligopeptides containing FMDP 7 and 8, the
peptide-nucleoside antibiotic nikkomycin X/Z 9, and a human
salivary polypeptide histatin 5. A set of the antifungal amino acids
included the following: L-Asp--hydroxamate 10, OLys 11, FPhe
12, cis-pentacin 13, 6-diazo-5-oxo-L-norleucine (DON) 14, and
azaserine 15 (Fig. 1). Fluconazole was included as a reference to
confirm the susceptibility/resistance of each strain.
TABLE 1. Microbial strains used in this study
Strain Description Source or reference
S. cerevisiae ATCC 9763 Wild type ATCC
S. cerevisiae AD12345678 MAT pdr1-3 his ura3 pdr5 snq2 pdr10 pdr11 pdr15 yor1 ycf1 9
S. cerevisiae ADCDR1 AD12345678 transformed with CDR1 42
S. cerevisiae ADCDR2 AD12345678 transformed with CDR2 42
S. cerevisiae ADMDR1 AD12345678 transformed with MDR1 14
C. albicans ATCC 10261 Wild type ATCC
C. albicans Gu4 Clinical isolate (fluconazole sensitive) 11
C. albicans Gu5 Clinical isolate (fluconazole resistant due to the overexpression of CDR1 and CDR2) 11
C. albicans B3 Clinical isolate (fluconazole sensitive) 11
C. albicans B4 Clinical isolate (fluconazole resistant due to the overexpression of MDR1) 11
FIG. 1. Structures of amino acid antifungals 10 to 15 used in this
study.
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The results of the determination of antifungal in vitro activ-
ities of oligopeptidic antifungals against the S. cerevisiae strains
are shown in Table 2. The yeast MDR genes disrupted in AD
cells did not significantly change the strain’s drug susceptibility
profile, in comparison to the control ATCC 9763 strain, apart
from a barely detectable increase in sensitivity to fluconazole.
The ADCDR1, ADCDR2, and ADMDR1 strains were much
less susceptible to fluconazole than AD. In contrast, the
ADCDR1 and ADCDR2 strains showed enhanced susceptibil-
ities to several oligopeptide antifungals. The strongest effects,
reflected in the AD MIC/ADCDR1 MIC or AD MIC/ADCDR2
MIC ratios in the 64-fold/8-fold range, were observed for Leu-
FPhe, Met-Met-FPhe, Nva-FMDP, Lys-Nva-FMDP, and ni-
kkomycin. For other oligopeptides, the MIC ratios were in the
two- to fourfold range. The ADMDR1 transformant showed
an oligopeptide antifungal susceptibility comparable to that of
the parent AD strain, despite a marked increase in resistance
to fluconazole. A salivary polypeptide histatin 5 showed com-
parable activity against all strains.
The results of the determination of growth inhibitory activ-
ities of antifungal amino acids presented in Table 3 showed a
few cases of slightly different susceptibilities of the MDR
strains to L-Asp--hydroxamate, FPhe, OLys, DON, and aza-
serine. FPhe, OLys, DON, and azaserine were only slightly
more active (two- to fourfold) against ADCDR1 and AD-
CDR2 cells than against the parent AD strain. All MDR trans-
formants showed decreased susceptibilities to cis-pentacin.
MICs of antifungal amino acids, oligopeptides, and flucon-
azole against C. albicans clinical isolates Gu4 and B3, pre-
sented in Table 4, were similar to those found for the reference
ATCC 10261 strain. Strains Gu5 and B4 were strongly resistant
to fluconazole. Compared with Gu4, Gu5 cells overexpressing
CDR1 and/or CDR2 showed enhanced susceptibilities to oli-
gopeptides 2 and 5 to 9. Gu4 MIC/Gu5 MIC ratios were in the
4- to 16-fold range, and the highest values were found for
OLys-Leu-Gly and Leu-FPhe. In B4, overexpression of MDR1
had little or no effect on the susceptibilities of C. albicans cells
to oligopeptides 2 and 5 to 9 and amino acid antifungals 10 to
12, 14, and 15. All C. albicans strains were equally susceptible
to histatin 5. Gu5 cells were slightly more susceptible to OLys
11 and DON 14 than the Gu4 cells. No differences were found
for FPhe and azaserine. The MDR strains Gu5 and B4 were
less susceptible to cis-pentacin 13 than their parental strains.
Uptake of amino acid and oligopeptide antifungals by MDR
yeast cells and intracellular processing of oligopeptides. The
antifungal action of all oligopeptide and amino acid antifun-
gals used in this study is antagonized by proteinogenic oli-
gopeptides or amino acids, respectively, which compete for
uptake into the fungal cells via oligopeptide or amino acid
permeases (4, 8, 21, 26, 28, 43, 46, 47). To test whether the
presence and activity of drug-effluxing transporters affected
oligopeptide or amino acid transport, the uptake rates of these
compounds, alanine, Ala-Ala, and Ala-Ala-Ala, were deter-
mined.
The uptake rates of oligopeptides and amino acids tested
were constant for at least 15 to 20 min and then gradually
decreased. These properties allowed the determination of ini-
tial uptake velocities. The rates were corrected for passive
TABLE 2. In vitro fungistatic activities of oligopeptide antifungals
and fluconazole against S. cerevisiae reference and
recombinant strains
Oligopeptide
MIC (g/ml) of a:
ATCC
9763 AD ADCDR1 ADCDR2 ADMDR1
5FO-Leu-Leu (1) 512 512 128 256 512
OLys-Leu-Gly (2) 8 4 1 1 4
OLys-Leu-Leu-Gly (3) 64 64 16 32 64
OLys-Leu-Leu-Leu-
Gly (4)
256 256 128 128 256
Leu-FPhe (5) 256 256 8 4 256
Met-Met-FPhe (6) 256 512 32 32 256
Nva-FMDP (7) 4 4 0.5 1 4
Lys-Nva-FMDP (8) 32 32 4 8 32
Nikkomycin (9) 128 128 16 16 128
Histatin 5 128 128 128 128 128
Fluconazole 2 1 32 16 32
a MICs were determined as described in Materials and Methods by the mi-
crotiter serial twofold dilution method using the YNBG-proline medium con-
taining 2% glucose. Inoculum size was 105 CFU/ml. Plates were incubated for
24 h at 30°C.
TABLE 3. In vitro fungistatic activities of amino acid antifungals
against S. cerevisiae reference and recombinant strains
Amino acid
MIC(s) (g/ml) of a:
ATCC
9763 AD ADCDR1 ADCDR2 ADMDR1
Asp--hydroxamate
(10)
256 256 64 64 128
OLys (11) 8 8 2 4 16
FPhe (12) 32 32 16 16 32
cis-pentacin (13) 64, 4b 128, 8b 256, 16b 256, 16b 256, 16b
DON (14) 0.5 0.5 0.125 0.25 0.5
Azaserine (15) 2 2 1 1 2
a MIC(s) determined under conditions described in Table 2.
b MICs determined by using the YNBG medium containing 1 mg/ml of l-
glutamate instead of l-proline as the main nitrogen source.
TABLE 4. In vitro susceptibilities of Candida albicans reference
strain and clinical isolates to oligopeptide and amino acid
antifungals and fluconazole
Compound
MIC (g/ml) of a:
ATCC
10261 Gu4
Gu5 (CDR1
and/or
CDR2)
B3 B4(MDR1)
OLys-Leu-Gly (2) 128 256 16 64 32
Leu-FPhe (5) 64 128 8 64 64
Met-Met-FPhe (6) 128 128 32 128 128
Nva-FMDP (7) 2 2 0.125 4 4
Lys-Nva-FMDP (8) 8 4 1 8 8
Nikkomycin (9) 32 16 4 8 8
Histatin 5 32 32 32 32 32
Asp--hydroxamate (10) 256 256 128 256 256
OLys (11) 16 16 4 16 32
FPhe (12) 256 128 128 128 128
cis-pentacin (13) 1 1 4 2 8
DON (14) 4 4 1 4 4
Azaserine (15) 16 16 16 32 32
Fluconazole 4 8 256 4 64
a MICs were determined by using RPMI-1640 buffered medium, as described
in Materials and Methods. No growth inhibition was observed for oligopeptides
1, 3, and 4 at a concentration of 1,024 g/ml.
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binding of the compounds tested by measuring uptake in the
presence of NaN3, accounting for less than 3% of the initial
rate of oligopeptide/amino acid uptake.
The results of the determination of the initial uptake rates of
compounds 1 to 9 and the model (Ala)2 and (Ala)3 oligopep-
tides are presented in Table 5. The initial uptake rates of com-
pounds 1 to 9 into AD cells were in each case lower than those of
the alanyl oligopeptides, but the ADCDR1 and ADCDR2 cells
took up all the oligopeptides tested 1.5- to 3-fold faster than the
AD strain. Uptake rates for the ADMDR1 strain were virtually
identical to those of the AD strain. A 10-min pretreatment with
fluconazole of ADCDR1 and ADCDR2 cells, but not AD or
ADMDR1 cells, enhanced by up to 10% the uptake of Ala-Ala
and the oligopeptide antifungals OLys-Leu-Gly, Leu-FPhe,
and nikkomycin. Histatin 5 was taken up slowly (0.6  0.05
nmol/min/mg dry weight) by all strains, but there was no sub-
stantial difference between AD and AD-derived cells. A com-
parison of Tables 5 and 2 suggests that all cases of increased
transport rates of oligopeptide antifungals correlated with en-
hanced susceptibilities of MDR cells to these compounds.
There was no direct correlation between susceptibilities (Table
3) and uptake rates (Table 6) for amino acid antifungals.
Antifungal action of oligopeptides 1 to 8 requires intracel-
lular cleavage to release an active enzyme inhibitor. The rate of
this cleavage could affect the antifungal activity of oligopep-
tides. The cleavage rates obtained for cell extracts prepared
from ATCC 9763, AD, ADCDR1, ADCDR2, and ADMDR1
cells were all within the 14 to 25 nmol/min/mg protein range
(data not shown). There was no statistically significant differ-
ence between the cleavage rates for a particular oligopeptide
determined in extracts from cells lacking or overexpressing
MDR transporters. These measurements indicated that intra-
cellular cleavage did not limit the activities of oligopeptide
antifungals 1 to 8. Nikkomycin 9 and histatin 5 were very slowly
cleaved (the rates were 0.4 to 0.5 and 0.1 to 0.15 nmol/min/mg
protein, respectively); however, both of these agents act on the
targets in an intact form (15, 46). The cleavage rates deter-
mined for C. albicans ATCC 10261, Gu4, Gu5, B3, and B4 cells
were slightly higher (20 to 32 nmol/min/mg protein for com-
pounds 1 to 8 and 0.3 to 0.8 nmol/min/mg protein for nikkomy-
cin and histatin 5), and there was no significant difference
between MDR and sensitive strains.
Changes in intra- and extracellular pH in MDR yeast
strains. We previously found that yeast mutants overexpress-
ing CDR1 had demonstrated enhanced proton-extruding activ-
ity (27). To test if the enhanced rates of uptake of oligopep-
tides and amino acids in cells overexpressing CDR1 and/or
CDR2 might result from modifications of plasma membrane
electrochemical potential, the intracellular pH and the rates of
glucose-dependent proton efflux were measured. The intracel-
lular pH was monitored using CFDA-SE as a fluorescent
probe. The results of this experiment, presented in Fig. 2, show
that probe-loaded, glucose-deprived yeast cells maintain an
intracellular pH in the range of 5.4 to 5.6. This relatively low
intracellular pH, compared with that determined in other stud-
ies (7, 20), may be due to the deactivation of the plasma
membrane H-ATPase, Pma1p (2), at a low pH in the absence
of glucose (43). The glucose addition, while only slightly in-
creasing the intracellular pH of the AD and ADMDR1 cells,
markedly increased the intracellular pHs of ADCDR1 and
ADCDR2 cells. Subsequent addition of fluconazole further
alkalinized the cytoplasm of ADCDR1 and ADCDR2 cells,
but the intracellular pHs of AD and ADMDR1 remained es-
sentially unchanged. The addition of fluconazole without a
prior glucose addition did not significantly increase the intra-
TABLE 5. Initial rates of oligopeptide uptake by yeast mutants
Oligopeptide
Initial transport rate (nmol/min/mg dry wt)  SD of a:
AD ADCDR1 ADCDR2 ADMDR1
Ala-Ala 2.55  0.38b 4.20  0.47b 3.94  0.50b 2.61  0.35b
2.58  0.32 4.46  0.51 4.08  0.44 2.59  0.33
Ala-Ala-Ala 3.15  0.45 5.30  0.57 4.74  0.60 2.91  0.25
OLys-Leu-Gly (2) 0.70  0.07b 1.32  0.06b 1.26  0.08b 0.85  0.08b
0.69  0.08 1.42  0.09 1.31  0.10 0.87  0.06
OLys-Leu-Leu-Gly (3) 0.51  0.18 0.83  0.16 0.96  0.12 0.65  0.08
OLys-Leu-Leu-Leu-Gly (4) 0.31  0.12 0.49  0.13 0.51  0.11 0.28  0.08
Leu-FPhe (5) 0.79  0.08b 1.82  0.04b 2.23  0.12b 0.87  0.11b
0.79  0.07 1.95  0.11 2.37  0.21 0.84  0.09
Met-Met-FPhe (6) 0.64  0.09 1.11  0.14 1.23  0.16 0.67  0.10
Nva-FMDP (7) 0.96  0.09 1.86  0.11 1.56  0.13 1.02  0.10
Lys-Nva-FMDP (8) 0.79  0.05 1.61  0.12 1.18  0.09 0.81  0.09
Nikkomycin (9) 0.32  0.02b 0.98  0.03b 0.88  0.06b 0.34  0.04b
0.33  0.05 1.08  0.08 0.97  0.08 0.32  0.05
a Initial uptake rates were determined as described in Materials and Methods. Values are the means of three determinations  the standard deviation (SD).
b Cells were pretreated with fluconazole for 10 min.
TABLE 6. Initial rates of amino acid uptake by yeast mutants
Amino acid
Initial transport rate
(nmol/min/mg dry wt)  SD of a:
AD ADCDR1 ADCDR2 ADMDR1
Ala 3.51  0.56 4.16  0.38 4.35  0.41 3.33  0.33
Asp--hydroxamate (10) 1.54  0.16 2.25  0.42 1.69  0.11 1.25  0.13
FPhe (11) 1.48  0.16 1.81  0.18 1.44  0.12 1.36  0.15
OLys (12) 1.78  0.11 2.57  0.15 1.86  0.06 1.63  0.07
Cispentacin (13) 1.63  0.20 2.11  0.21 1.85  0.16 1.67  0.18
DON (14) 2.0  0.22 2.32  0.31 2.25  0.16 1.98  0.19
Azaserine (15) 1.75  0.23 2.15  0.17 1.92  0.22 1.70  0.17
a Conditions of the determination were as described in Table 5. Values are the
means of three determinations  the standard deviation (SD).
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cellular pH. Thus, metabolic energy is needed for fluconazole-
induced enhancement of intracellular pH.
Glucose-dependent proton efflux was monitored in unbuf-
fered cell suspensions adjusted to pH 5.2  0.05 (Fig. 3). The
ADCDR1 and ADCDR2 cells extruded protons 1.5 to 2-fold
more rapidly than the AD or ADMDR1 cells. These results
confirm previous observations made for the CDR1-containing
transformants (27) and indicate that overexpression of Cdr1p
or Cdr2p causes similar effects. The same phenomenon was
observed for C. albicans clinical isolates overexpressing CDR1
and CDR2 but not MDR1. Vanadate, an inhibitor of the in
vitro ATPase activity of the fungal Pma1p and ABC transport-
ers (6), partially inhibited proton efflux in all types of cells
tested.
The differences in glucose-dependent internal pH and glu-
cose-dependent proton pumping between the cells overex-
pressing the ABC transporters and the control and ADMDR1
strains suggested that overexpression of ABC transporters in-
creased the plasma membrane electrochemical potential. The
susceptibilities of yeast cells to the protein synthesis inhibitor
hygromycin B are pH dependent, and resistance has been
correlated with depolarization of the plasma membrane in
pma1 mutants (33). The antifungal activity of hygromycin B
was determined for mutant yeast cells used in this study. The
hygromycin MICs were as follows: 128, 64, 32, and 128 g/ml
for the AD, ADCDR1, ADCDR2, and ADMDR1 cells, re-
spectively.
Oligopeptides and amino acids are not substrates for Cdr1p
and Cdr2p. Cells deenergized with 2DG and suspended in
buffer (pH 4.0) were loaded with an amino acid or oligopeptide
and then reenergized by a glucose addition at pH 6.0, thus
triggering possible efflux. Cdr1p and Cdr2p functionality in the
reenergized cells was confirmed using rhodamine 6G as a
probe. During the 60-min loading, the cells accumulated 32 to
67% of each amino acid/oligopeptide. No fluorescamine-pos-
itive compounds were detected in spent medium samples col-
lected from the AD, ADCDR1, and ADCDR2 cell suspensions
loaded with most of the antifungal compounds tested and
reenergized with glucose at pH 6.0. The only exception was the
extrusion of cis-pentacin 13 from the ADCDR1 and ADCDR2
cells (5  2 M of the fluorescamine–cis-pentacin conjugate
was detected after 30 min). These results show that all oli-
gopeptides and amino acids tested, except cis-pentacin, are not
extruded by Cdr1p and Cdr2p.
DISCUSSION
MDR yeast strains overexpressing CDR1 show strikingly in-
creased susceptibilities to antifungal FMDP oligopeptides
(27). The present work has shown that recombinant yeast and
clinical C. albicans isolates overexpressing CDR1 and/or CDR2
genes are more susceptible to several different antifungal oli-
gopeptides than their respective parental strains lacking these
genes or expressing them at the basal level. On the other hand,
yeast strains overexpressing the MDR1 gene showed suscepti-
bilities to all oligopeptides similar to those of their parental
strains. The enhanced susceptibilities to numerous oligopep-
tide antifungals, which represent a broad range of structures
and mechanisms of antifungal action, appear to be a feature of
MDR yeast strains overexpressing the Cdr1p and Cdr2p ABC
drug transporters.
We suggest that the enhanced susceptibility of MDR yeast
strains to oligopeptide antifungals is due to enhanced oli-
gopeptide antifungal uptake mediated by oligopeptide per-
meases that are affected by an increased membrane potential
induced by overexpression of the ABC drug efflux pumps
Cdr1p and Cdr2p. In yeast strains, the inward transport of
oligopeptides containing two to eight amino acid residues is
exclusively mediated by active transport systems involving per-
meases acting as ligand/H symporters (16, 34, 39). In con-
trast, and consistent with our observations, relatively large
antifungal polypeptides, like histatin 5, are internalized in an
energy-dependent manner via cell wall-located receptors (24),
while compounds known as the “cell-penetrating peptides”
cross the membrane by free diffusion (17). The presence of the
peptide permeases makes the yeast cells susceptible to the
action of oligopeptide antifungals targeting intracellular en-
zymes. Some of these compounds, including nikkomycin 9,
attack their targets in an intact form (46). Other oligopeptides,
FIG. 3. Initial rates of proton efflux by yeast mutants. The rates
were determined by monitoring pH changes of yeast cell suspensions.
Cells were transferred from the minimal growth medium to unbuffered
water, and pH changes were recorded after glucose addition. Each bar
represents the mean of three independent determinations  the stan-
dard deviation (SD).
FIG. 2. Changes in the intracellular pH of yeast cells caused by
glucose and fluconazole addition. Yeast cells suspended in a buffer at
pH 4.0 were starved of glucose and loaded with CFDA-SE. Cells were
then suspended in buffer, pH 4.5, and treated with glucose and flu-
conazole. Samples were collected at time intervals, and fluorescence at
excitation of 435 and 495 nm (F495 and F435) was measured at 525 nm.
F495 and F435 ratios were used to calculate the intracellular pH values.
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like compounds 1 to 8, are cleaved intracellularly by pepti-
dases, and the released enzyme inhibitor is then able to reach
its target (3, 4, 21, 28, 29, 43). The uptake of antifungal oli-
gopeptides, rather than their intracellular cleavage, appears to
be the rate-limiting step that determines their potency (25, 26).
Thus, the relatively slow accumulation of oligopeptides 1 to 9
by the AD cells, a substantial enhancement of this uptake in
AD-derived mutants overexpressing CDR1 or CDR2 and a
good match between the enhanced transport rates and the
increased antifungal activity, are consistent with the enhanced
susceptibilities to oligopeptide antifungals being due to accel-
erated uptake.
The enhanced rates of glucose-dependent proton efflux and
the fluconazole-stimulated alkalinization of the cytoplasm sug-
gested that the overexpression of the ABC transporters Cdr1p
and Cdr2p increased the membrane potential associated with
the yeast plasma membrane. This concept was confirmed by
demonstrating the enhanced susceptibilities of ADCDR1 and
ADCDR2 cells to hygromycin B. Consistent with a mechanism
in which the additional proton motive force drives proton gra-
dient-dependent oligopeptide permeases, yeast isolate suscep-
tibility to histatin 5 was not increased in cells overexpressing
these two ABC transporters. The observed faster accumulation
of amino acids by ADCDR1 and ADCDR2 was also most
likely due to the increased membrane potential, since these
compounds are transported into yeast cells by proton motive
force-dependent permeases (5, 19, 38).
The molecular basis of pH changes observed in yeast cells
expressing the ABC drug transporters has yet to be ex-
plained. They may result from a disturbance of physical
properties of the cell membrane or be due to stimulation of
proton export mediated by ABC drug transporters or other
membrane proteins. The transmembrane proton gradient in
yeast cells is normally maintained by the vanadate-sensitive
plasma membrane proton pump Pma1p (2, 41). In this study,
proton efflux was partially inhibited by vanadate in all cell
types. Vanadate inhibits the ATP hydrolytic activity of both
ABC transporters and Pma1p in plasma membrane prepa-
rations (22), but its effects on these activities in whole cells
are not known. Nevertheless, stimulation of Pma1p activity
due to the changes in membrane properties cannot be ex-
cluded. Another possibility is proton-effluxing activities of
Cdr1p and Cdr2p, similar to those of human Mdr1p ex-
pressed in S. cerevisiae, found by Fritz et al. (12). This
possibility may be supported by the fact that fluconazole
efflux in ADCDR1 and ADCDR2 cells gave stronger alka-
linization to the cytoplasm and a higher uptake rate of
oligopeptide antifungals. It may be possible as well that the
observed higher glucose-induced internal alkalinization of
ADCDR1 and ADCDR2 cells was due to Cdr1p or Cdr2p
proton-effluxing activity, since those cells were prestarved
under conditions ensuring deactivation of Pma1p. Further
studies are necessary to explore and exploit the possibilities.
Nevertheless, we conclude that the phenomenon of the en-
hanced susceptibilities of yeast cells overexpressing the
ABC-type MDR transporters to a broad range of oligopep-
tidic antifungals results from an accelerated uptake driven
by an additional proton motive force created in these cells.
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